| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Frank Tacke | Q62748536 |
| P2093 | author name string | Daniela C. Kroy | |
| P2860 | cites work | Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants | Q24563991 |
| From non-A, non-B hepatitis to hepatitis C virus cure | Q26864968 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions | Q33780105 | ||
| AASLD guidelines for treatment of chronic hepatitis B. | Q34501660 | ||
| The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 | Q34533596 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies | Q35949997 | ||
| Overview of hepatitis B viral replication and genetic variability | Q36807341 | ||
| Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. | Q38023098 | ||
| Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. | Q38071396 | ||
| Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs | Q38446397 | ||
| Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis | Q38654142 | ||
| Emerging drugs for the treatment of hepatitis B. | Q38759805 | ||
| New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus | Q38809532 | ||
| Discontinuation of oral antivirals in chronic hepatitis B: A systematic review | Q38813725 | ||
| Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains | Q39213627 | ||
| Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains | Q39649139 | ||
| Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation. | Q39716344 | ||
| The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains | Q39876916 | ||
| Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. | Q40543517 | ||
| Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. | Q41538789 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
| Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir | Q44038236 | ||
| Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. | Q44047772 | ||
| Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. | Q44355905 | ||
| Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient | Q45387814 | ||
| Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. | Q45423363 | ||
| Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation | Q46707913 | ||
| Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. | Q46778386 | ||
| Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion | Q56968246 | ||
| Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study | Q58097173 | ||
| Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B | Q82240888 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 334 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Treatment for hepatitis B in patients with drug resistance | |
| P478 | volume | 4 |
| Q45325386 | Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. |
| Q59355375 | Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient |
| Q59351826 | Evaluation of drug resistance mutations in patients with chronic hepatitis B |
| Q47147841 | Kushenin combined with adefovir dipivoxil affects the HBV-DNA load in serum, immune functions and liver functions of patients with chronic hepatitis B. |
| Q33800724 | TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China |
Search more.